Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 135 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M2KyfWN6fG:2b4jpZ{BCe3OjeR?= NXLNeGtMPzJiaB?= MlLsSG1UVw>? NIDS[4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGW6cILld5NqdmdiUFmzT4FteGijIFW1OFVMKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFAyPThizszN MXeyOFkxODJ4Nh?=
DU145 NFfaeJVEgXSxdH;4bYMhSXO|YYm= MnzRO|IhcA>? NYrxSYl1TE2VTx?= NX;UTlFZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN M{\5clI1QTByMk[2
A2780 NGm2WXJEgXSxdH;4bYMhSXO|YYm= MlvjO|IhcA>? NFXIZo1FVVOR NInrTXVEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN NFi0R4szPDlyMEK2Oi=>
U87MG Mn7PR5l1d3SxeHnjJGF{e2G7 Mn;EO|IhcA>? NUfybYhpTE2VTx?= NYTkcFR6S3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjl6IN88US=> Mkj5NlQ6ODB{Nk[=
A2780 NGDJb4tHfW6ldHnvckBCe3OjeR?= M3fOPFEhcA>? MXrEUXNQ NEO2eJJKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hf2m2aDDFR|UxKG:oIECuNFU2KM7:TR?= MYOyOFkxODJ4Nh?=
DU145 NGq4SVZHfW6ldHnvckBCe3OjeR?= MmTVNUBp NX3TU|k1TE2VTx?= NEWwVGNKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hTFVzNEWgZ4VtdHNiaHHyZo9zcW6pIFzLRlEhdXW2YYTpc44hf2m2aDDFR|UxKG:oIECuNFc{KM7:TR?= MXmyOFkxODJ4Nh?=
A2780 M3H1cWZ2dmO2aX;uJGF{e2G7 M3;IXlEhcA>? MlrYSG1UVw>? NVvwbYVUUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJGEzPzhyIHPlcIx{KHerdHigSWM2OCCxZjCwMlA4PCEQvF2= M2rVflI1QTByMk[2
MCF7 NVfEXGdtTnWwY4Tpc44hSXO|YYm= M3TjOVEhcA>? MU\EUXNQ NWOwfpE3UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgSVU1PUtibYX0ZY51NW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlEh|ryP NXOyToh6OjR7MECyOlY>
U87MG MU\GeY5kfGmxbjDBd5NigQ>? NGHjSo0yKGh? NGPDclNFVVOR NH3wSoxKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR|UxKG:oIECuNVMh|ryP NGmxXWYzPDlyMEK2Oi=>
A2780 NVjUVmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HCcFczKGh? NGfkOmRFVVOR M3Ox[GVEPTB;MD61NkDPxE1? M1PFUFI1QTByMk[2
SKMES-1 MoTLR5l1d3SxeHnjJGF{e2G7 M3\UVFEh|ryP M1nlPFczKGh? M2LENGlv\HWlZYOgZ4VtdCCmZXH0bC=> MmfZNlYxOTN|MUi=
H596 NEXQUnBHfW6ldHnvckBCe3OjeR?= NWj4XXppOSEQvF2= NVvzRopiUW2yYXnyd{Bk\WyuIH3p[5JifGmxbh?= MnmyNlYxOTN|MUi=
HCC2450 M4Pl[2Z2dmO2aX;uJGF{e2G7 MYmxJO69VQ>? M4\xWWlueGGrcoOgZ4VtdCCrbo\hd4lwdg>? M1zoWVI3ODF|M{G4
A549 NFT0NGZHfW6ldHnvckBCe3OjeR?= NI\IbFQ2ODBibl2= NGHYSWE1QCCq M1fzWGROW09? MWfJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? MorXNlU6Ozd{OUm=
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexJO69VQ>? NFPwZXM4OiCq MULEUXNQ NULocZg4UW6qaXLpeJMh[2WubDDndo94fGh? Mn;DNlU6Ozd{OUm=
H522 NVLhUWlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TKdlEh|ryP M3\xSVczKGh? MWPEUXNQ NGnKdXlKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIrCTYEzPTl|N{K5PS=>
LNCaP M1HLNmZ2dmO2aX;uJGF{e2G7 M4rGfVEh|ryP NFXvTZZUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= NY[xbox[OjV|NkC3PVk>
LNCaP95 MoTmSpVv[3Srb36gRZN{[Xl? NWL2dXFbOSEQvF2= MkjXV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? M3e2PFI2OzZyN{m5
HCT-15 MWfBdI91d3OrczDBd5NigQ>? MWqxNEDPxE1? NX3TPXlQPDhiaB?= MoDoSG1UVw>? Ml;YTY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUG1JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NWnOeoVbOjVzNUKyOFU>
HCT-116 NGLJfFVCeG:2b4Ppd{BCe3OjeR?= NHfVVGkyOCEQvF2= NFHOcJY1QCCq MYLEUXNQ M13rW2lv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xNVYh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NHHaem0zPTF3MkK0OS=>
NCI-H460 M3XTeGFxd3Sxc3nzJGF{e2G7 NGH3eVkyOCEQvF2= NETSOWY1QCCq NGWyZZRFVVOR NITEfYJKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u NFu2WIYzPTF3MkK0OS=>
SKOV-3 Mn\0RZBwfG:|aYOgRZN{[Xl? MnvvNVAh|ryP NYfJd5JFPDhiaB?= NGPYTlVFVVOR MkOxTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NX;rZ5BwOjVzNUKyOFU>
BSY-1 NFr4[3hCeG:2b4Ppd{BCe3OjeR?= M4fZdVExKM7:TR?= Mo\jOFghcA>? MlX5SG1UVw>? NX7JN|lLUW6mdXPld{BieG:ydH;zbZMhcW5iQmPZMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M4\aTVI2OTV{MkS1
MKN-1 MmfIRZBwfG:|aYOgRZN{[Xl? M3nSd|ExKM7:TR?= NEW4NmY1QCCq MY\EUXNQ NF\1eZpKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NYLGcGNXOjVzNUKyOFU>
NCI-H522 Mn3NRZBwfG:|aYOgRZN{[Xl? NVHETmFDOTBizszN NGHvW3c1QCCq NVHrOlgyTE2VTx?= M{PjcGlv\HWlZYOgZZBweHSxc3nz NFfVS4EzPTF3MkK0OS=>
OVCAR-3 M3m1ZWFxd3Sxc3nzJGF{e2G7 M2fHbFExKM7:TR?= NVjRe5ZqPDhiaB?= M4XhbWROW09? MWrJcoR2[2W|IHHwc5B1d3Orcx?= NVK5TGJtOjVzNUKyOFU>
HBC-5 MYrBdI91d3OrczDBd5NigQ>? NFi3c|EyOCEQvF2= MnPyOFghcA>? NIPqTnNFVVOR NWTUVYg5UW6mdXPld{BieG:ydH;zbZM> NUHaR2V2OjVzNUKyOFU>
RXF-631L MWPBdI91d3OrczDBd5NigQ>? NEnB[pUyOCEQvF2= NV\jUYxyPDhiaB?= M{DuVGROW09? NUHhNnB5UW6mdXPld{BieG:ydH;zbZM> MmPuNlUyPTJ{NEW=
MKN-45 NFe5V4NCeG:2b4Ppd{BCe3OjeR?= MUOxNEDPxE1? NU\zPY53PDhiaB?= NVe2ZpF4TE2VTx?= MlPCTY5lfWOnczDhdI9xfG:|aYO= NYXhPXZZOjVzNUKyOFU>
BON-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\QT|UxOCCwTR?= MXmxNEBl MU\EUXNQ M2XoVGlvcGmkaYTzJINmdGxiZ4Lve5Rp M3PvZ|I2ODJ4Mkmy
BON-1 M4\wSGZ2dmO2aX;uJGF{e2G7 MWK1NFAhdk1? NFK1eG81KGh? MVnEUXNQ MVPJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGTodlMxQCCjbnSgV4VzPDd| MoDONlUxOjZ{OUK=
QGP-1 NU\VboFPTnWwY4Tpc44hSXO|YYm= M3HRXFUxOCCwTR?= NI\5THY1KGh? NUTFO|F[TE2VTx?= NHX1THNKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NH\WUZAzPTB{NkK5Ni=>
Huh7 MV7GeY5kfGmxbjDBd5NigQ>? M33yPVEh|ryP MVmxJIg> M4GydWROW09? MYDJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? MUmyOVAxPDRyMx?=
BNL MXHGeY5kfGmxbjDBd5NigQ>? NVz0dWJtOSEQvF2= MmDZNUBp NHzofGZFVVOR MnfFTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 MUKyOVAxPDRyMx?=
MDA-MB-175 NV;0WmpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGxJO69VQ>? MnnwOUBl MYTEUXNQ NHvaXGlKSzVyPEGg{txO MWiyOFg4QTd7Nh?=
MDA-MB-134 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Cc|Eh|ryP NHvvXHU2KGR? NX3se3dzTE2VTx?= MWXJR|UxRDFizszN MWiyOFg4QTd7Nh?=
HCC1500 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HSSVEh|ryP M4TvNFUh\A>? NXT4dZB4TE2VTx?= MmfLTWM2ODxzIN88US=> NEDXbHIzPDh5OUe5Oi=>
EFM-19 NUjGTZNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXtWJVLOSEQvF2= NVf1PHhYPSCm MoTDSG1UVw>? MV7JR|UxRDFizszN NULRUlM2OjR6N{m3PVY>
ZR-75-30 M3GyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPpNUDPxE1? NGjFSIo2KGR? NGjHXXhFVVOR M176ZmlEPTB:MTFOwG0> M4nnXVI1QDd7N{m2
MDA-MB-361 M{Ht[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7WSXoyKM7:TR?= NU\DOFkzPSCm NV73XWc6TE2VTx?= M{XpZmlEPTB:MTFOwG0> MUKyOFg4QTd7Nh?=
T-47D NVTQUFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDzelJtOSEQvF2= NHHyWVI2KGR? MlX6SG1UVw>? M{\EdmlEPTB:MTFOwG0> NGDFblgzPDh5OUe5Oi=>
SK-BR-3 M1u2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVryUoVlOSEQvF2= M3\0NFUh\A>? NIPT[HFFVVOR MnqyTWM2ODxzIN88US=> NFTBPZgzPDh5OUe5Oi=>
UACC-732 M4rtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3DNUDPxE1? NIXRRYQ2KGR? MnXsSG1UVw>? Mn3tTWM2ODxzIN88US=> MViyOFg4QTd7Nh?=
BT-474 NFvFUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnJcXgyKM7:TR?= NV3jbnpnPSCm MYLEUXNQ M3zUU2lEPTB:MTFOwG0> M2X5OFI1QDd7N{m2
HCC202 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjCZo1iOSEQvF2= NV6zTINWPSCm M1H2fGROW09? NXTnOXZ4UUN3MEyxJO69VQ>? M1r4RlI1QDd7N{m2
MCF7 NU\Wd403T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXYZ|MyKM7:TR?= NUDPVm1bPSCm NEHTTJpFVVOR MXLJR|UxRDFizszN MlX2NlQ5Pzl5OU[=
MDA-MB-415 NF3jdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxJO69VQ>? M3[4SFUh\A>? MWfEUXNQ MYLJR|UxRDFizszN NIDEenIzPDh5OUe5Oi=>
MDA-MB-453 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DyWlEh|ryP M2SweVUh\A>? M1TVSmROW09? NGTOWHpKSzVyPEGg{txO M2rZNFI1QDd7N{m2
ZR-75-1 NIjMdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;yNUDPxE1? MXm1JIQ> NHfrTolFVVOR MWjJR|UxRDFizszN M4S3RlI1QDd7N{m2
HCC38 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{naUFEh|ryP M{nFTFUh\A>? M4PXWWROW09? NEfKPWpKSzVyPEGg{txO NHz5WVkzPDh5OUe5Oi=>
HCC1419 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITCOnUyKM7:TR?= NVnjS5I5PSCm NGTYOGpFVVOR MYHJR|UxRDFizszN NYfQRXpyOjR6N{m3PVY>
UACC-812 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3QUlg3OSEQvF2= MnXHOUBl NICzXZpFVVOR NFnRV2JKSzVyPEGg{txO M4DEflI1QDd7N{m2
HCC1187 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDtNUDPxE1? M3zsNFUh\A>? NYqzS|JLTE2VTx?= MXnJR|UxRDFizszN NXP4PYlYOjR6N{m3PVY>
KPL-1 M3PWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRflEh|ryP MkDOOUBl NYDMUZlTTE2VTx?= NWPQ[4ZPUUN3MEyxJO69VQ>? MV6yOFg4QTd7Nh?=
SUM-225 NF[1T4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[5eVYyKM7:TR?= Mo\5OUBl MWrEUXNQ NE\GR5RKSzVyPEGg{txO M3LUc|I1QDd7N{m2
EFM-192A M{TZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfueHpuOSEQvF2= NG\wXYg2KGR? MkLpSG1UVw>? Mn\ZTWM2ODxzIN88US=> Mom0NlQ5Pzl5OU[=
JIMT-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3TW0{OSEQvF2= M{LZOVUh\A>? NUWySmVWTE2VTx?= MYLJR|UxRDFizszN MYqyOFg4QTd7Nh?=
HCC1143 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxJO69VQ>? M4rz[lUh\A>? MVTEUXNQ M1i5SmlEPTB:MTFOwG0> Mn\PNlQ5Pzl5OU[=
HCC2218 NVjUSW1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxSWxqOSEQvF2= NWLYWpp6PSCm MYfEUXNQ MYXJR|UxRDFizszN M4DrdlI1QDd7N{m2
MDA-MB-468 NHXYWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xJO69VQ>? NVnYOXhEPSCm NH;kWlRFVVOR NF3wenlKSzVyPEGg{txO M2HQcVI1QDd7N{m2
BT-20 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjUc3R4OSEQvF2= M{jacVUh\A>? NUnCW4h{TE2VTx?= M2\UbWlEPTB:MTFOwG0> MXuyOFg4QTd7Nh?=
MDA-MB-435 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPGNUDPxE1? NIXMOHc2KGR? NGK1UFFFVVOR M13ZfGlEPTB:MTFOwG0> M4fMdlI1QDd7N{m2
BT-549 NYPEbXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nX[FEh|ryP NGHrXoY2KGR? NYPRXoJITE2VTx?= NEfpe3lKSzVyPEGg{txO MWCyOFg4QTd7Nh?=
HCC1806 NVzVbZJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;5bJEyKM7:TR?= MYK1JIQ> MnnWSG1UVw>? NW\UZVA4UUN3MEyxJO69VQ>? NH3WeGozPDh5OUe5Oi=>
HCC1937 NEfvdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKxJO69VQ>? NV\yVFN5PSCm MlnqSG1UVw>? MYLJR|UxRDFizszN MmezNlQ5Pzl5OU[=
Hs578T M3zC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW0NUDPxE1? MkXwOUBl NEOzV5JFVVOR MV\JR|UxRDFizszN NFfveIozPDh5OUe5Oi=>
LN18 NFq1OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPGbXVDOjBizszN M3v4VlczKGh? NYnqN3ptTE2VTx?= NWXIT|VDUUN3MEy1JO69VQ>? M3\LdVI1PzRzMEe0
LN229 NVXqW3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxZnczOCEQvF2= NETpSnk4OiCq M3vEbWROW09? MkG1TWM2ODx3IN88US=> Mke3NlQ4PDFyN{S=
LNZ308 NVTvfmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX30S|Z6OjBizszN NEPGSFY4OiCq NUfPdHFKTE2VTx?= MYrJR|UxRDVizszN M4n0SFI1PzRzMEe0
T98G NIL4ZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOyNEDPxE1? M3GwVVczKGh? NYjm[mIzTE2VTx?= NVPGT2RiUUN3MEy1JO69VQ>? NELUdo8zPDd2MUC3OC=>
U87 NYfoPGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOyNEDPxE1? MoDQO|IhcA>? NYCyPGZETE2VTx?= NYXwPGltUUN3MEy1JO69VQ>? NYnhS|NzOjR5NEGwO|Q>
LN18 MXzGeY5kfGmxbjDBd5NigQ>? MUG1JO69VQ>? NXu1eHdHOjRiaB?= M4jwRmROW09? MVfJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV NVz1SGpvOjR5NEGwO|Q>
LNZ308 M3TGUWZ2dmO2aX;uJGF{e2G7 M3LhVVUh|ryP M{DXSVI1KGh? NVfWeFFDTE2VTx?= MXnJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV M1fxbVI1PzRzMEe0
Saos-2 MXXGeY5kfGmxbjDBd5NigQ>? MkPZOVAh|ryP NX3jd3B4PDhiaB?= MXrJcohq[mm2czDj[YxtKGmwdnHzbY9v NGDKSnozPDd{N{[2NC=>
MG-63 Mk\kSpVv[3Srb36gRZN{[Xl? NF;tTm82OCEQvF2= NUfudGFxPDhiaB?= MlTBTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MlTmNlQ4Ojd4NkC=
SJSA-1 NWDvbGtiTnWwY4Tpc44hSXO|YYm= MX[1NEDPxE1? NF;lU|k1QCCq MoLjTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? Ml2wNlQ4Ojd4NkC=
Saos-2 M2n2UmZ2dmO2aX;uJGF{e2G7 NYfxXpFOPTBizszN NIPzboE1QCCq M4n2eWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MoeyNlQ4Ojd4NkC=
MG-63 MnfvSpVv[3Srb36gRZN{[Xl? MX[1NEDPxE1? MXS0PEBp M4i3RWlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NH:wVokzPDd{N{[2NC=>
SJSA-1 NXfBOVJWTnWwY4Tpc44hSXO|YYm= MoL2OVAh|ryP MYe0PEBp NXv2R3gyUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? NXzGZ5JGOjR5Mke2OlA>
Saos-2 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYbVNLPTBizszN MV:0PEBp M3XoUWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NEPm[5EzPDd{N{[2NC=>
MG-63 M2rBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nqUFUxKM7:TR?= MXu0PEBp MUjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NHXGZpIzPDd{N{[2NC=>
SJSA-1 NUHXZVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmOVAh|ryP NULx[mVYPDhiaB?= MX\Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NHvabowzPDd{N{[2NC=>
FaDu M3LwbmZ2dmO2aX;uJGF{e2G7 NEGzZ4k2KM7:TR?= NYHDUpJbOjRiaB?= NHzGdZFFVVOR NFrKdJFT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NWDCRVNwOjR4M{GxOFc>
EMT6 NVX2cZpVTnWwY4Tpc44hSXO|YYm= M4PrV|Uh|ryP MXSyOEBp MoKySG1UVw>? MkLxVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NYfaRpBZOjR4M{GxOFc>
HCT116 M3Lr[GZ2dmO2aX;uJGF{e2G7 MWK1JO69VQ>? MX[yOEBp MUDEUXNQ NIfSW49T\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MoLaNlQ3OzFzNEe=
U87 MmezSpVv[3Srb36gRZN{[Xl? NGSxPWk2KM7:TR?= MWOyOEBp M3y0ZWROW09? MYfS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= M1ryRVI1PjNzMUS3
GBM NVX0OVZpSXCxcITvd4l{KEG|c3H5 MV[y{txO MkWwOFhp NFrUPJlFVVOR NX7LSpRrcW6mdXPl[EBpcWeqZYKgcIV3\Wy|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>? NFvr[VgzPDVyMES5Ni=>
BON Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnt[WV2OS13zszN MVO3Nog> NH7hblll\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v NH3KU5EzPDR2M{WyNy=>
BON NFThbWNCeG:ydH;zbZMhSXO|YYm= M36zSFEuPc7:TR?= NWW2dFNZOjSq MojrbY5kemWjc3XzJIFxd3C2b4Ppdy=> NVzIR4RwOjR2NEO1NlM>
H1975 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rtcFAvOy17LkdOwG0> MoPIO|Jp NY\2WllbTE2VTx?= MUDJR|UxRTFwM{i1{txO NXfkcmRrOjR|M{e4OFY>
H1975 M2TSUWFxd3C2b4Ppd{BCe3OjeR?= M1zoeFLPxE1? M2XqUlI1cA>? NFO0eHNFVVOR NFzJNodqdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>? M2XtO|I1OzN5OES2
T-ALL MUjBdI9xfG:|aYOgRZN{[Xl? M3PZfIJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= NI\LfmYzPCCxcjC0PIg> M3nnfmROW09? MXvh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= MorwNlQ{OTB5M{[=
BCR-ABL NYLlN5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfONE4zPS1zMN88US=> M2LQNlRl Mk[2d4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? NFHKSFkzPDJ2NE[xNi=>
LC-1/SQSF MXLGeY5kfGmxbjDBd5NigQ>? M1O3bVPPxE1? MYmyOIg> NWTGV41NTE2VTx?= MUHk[YNz\WG|ZTDOVmYzKHC{b4TlbY4hdGW4ZXy= NX3mTplWOjN7OECwPVM>
Primary CLL cells MkfyRZBweHSxc3nzJGF{e2G7 MoLhNU0yOM7:TR?= MWG0PIg> NWXPclB5cW6mdXPld{BieG:ydH;zbZMhcW5iQ1zMJINmdGy|IHnu[IVx\W6mZX70JI9nKHC{b3fuc5N1cWNibXHyb4Vzew>? M{n1U|I{QDVyOEC3
Primary CLL cells MY\LbY5ie2ViQYPzZZk> M1m5SlLPxE1? NU\5dWoxOzCvaX6= Mkmz[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NIXjUIQzOzh3MEiwOy=>
Primary CLL cells NHLw[VBEgXSxdH;4bYMhSXO|YYm= NVjxeGNpOs7:TR?= MlHTNlRp MnTUbY5lfWOnczDj[YxtKGO7dH;0c5hq[2m2eR?= NYrBSJRNOjN6NUC4NFc>
human NSCLC cell lines MmPXRZBweHSxc3nzJGF{e2G7 MmjZNE4yOjVvNN88US=> MUOyOIg> NFPl[o5FVVOR MYHJR|UxeyC{YX7n[ZMh\nKxbTCwMlQuOs7:TR?= M{C2WFI{PTZ{NEey
human HCC cell lines Mn;tR4VtdCC4aXHibYxqfHliYYPzZZk> MUmwMlAxPS1zzszN M33O[FQ5cA>? MXrJR|UxRTIQvF2= NEDUWJkzOzR6OUm5PS=>
Huh7 NIHuXnZMcW6jc3WgRZN{[Xl? Ml;ZNe69VQ>? NH7ESFU1QGh? MULzbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S= MoDwNlM1QDl7OUm=
SK-HEP1 NIPZUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\z[lZsOS1{MN88US=> NVzDPYR1PzKq M{jVTWROW09? M3fBVWlEPTExvKyx{txO NYPDZlJZOjN2N{mxN|Y>
786-0 NYPQO3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXJRVMyNTJyzszN NFnq[W04Omh? M36wXmROW09? NEC3TnVKSzVy78{cNe69VQ>? MWqyN|Q4QTF|Nh?=
JVM2 M3Kxd2N6fG:2b4jpZ4l1gSCjc4PhfS=> M4K1fVAvOi1{MN88US=> M2XTVVczcA>? MWXEUXNQ M{TLbGlEPTB;MD65{txO Mk\ENlMzOzh4M{m=
EHEB MlXwR5l1d3SxeHnjbZR6KGG|c3H5 NH2zNI8xNjJvMkFOwG0> NVjmNZZZPzKq MYLEUXNQ NWeydXAzUUN3ME2wMlfPxE1? M4DVOVI{OjN6NkO5
MEC2 M3LGNGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFq5[5QxNjJvMkFOwG0> M4jtU|czcA>? Mn7jSG1UVw>? NV22[5VHUUN3ME2wMlfPxE1? MoOwNlMzOzh4M{m=
primary B-CLL lymphocytes MYDBdI9xfG:|aYOgRZN{[Xl? M3HocGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV? M{TOR|I1cA>? M2XVemROW09? MmHMTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> NHm0XXUzOzJ|OE[zPS=>
primary B-CLL lymphocytes NYrIZZVxU2mwYYPlJGF{e2G7 NVnNWpdHUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= NUjsRphwOjSq MX3pcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= NHrEdmMzOzJ|OE[zPS=>
human NSCLC NVnPWnhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HDWVAvPS1{zszN NXLxO2dXPzKq MVTJR|UxRTIQvF2= NFrLWJYzOjd6MUO5Ny=>
human NSCLC NFniSIpMcW6jc3WgRZN{[Xl? MWix{txO M2n2TVI1cA>? NI[0TJdqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 NUDxVHl1OjJ5OEGzPVM>
Y1 cell line NUPIdo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ScW0xNjIQvF2vNe69VQ>? M2fxNVI1cA>? NVi5[FliTE2VTx?= M{S5ZYlvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy| MVGyNlY6OjlyNB?=
PIK3CA-mutant MCF7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\VVpI6T0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= MlHGO|Jp MorBS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? M3\DOFIzPjV|OU[3
PIK3CA-mutant MCF7 M3PhNmtqdmG|ZTDBd5NigQ>? M3PCOmlEPTB;MUG0xtE{dk1? MXK3Nog> NXG4XndRUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=> M4i1cFIzPjV|OU[3
MCF7-myr-Akt M1\L[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPPS2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NF75OlY4Omh? Mmm0S2k2OD1{OUpCtVY5dk4xvJzMSFUx97zgMUCsNFAxdk1? NWDTZYFpOjJ4NUO5Olc>
colon cancer cell lines NG\YO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPTZmFWOC1zMN88US=> MXm3Nog> MWHEUXNQ NUnhVFZtUUN3ME2x{txO NWPVZ3FkOjJ3NEO4OVc>
gastric cancer cell lines NITod4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzPPW0xNTFyzszN Mn3hO|Jp MYrEUXNQ MXXJR|UxRTJvNd88US=> NYjFSY1ROjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 M1G3U2Fxd3C2b4Ppd{BCe3OjeR?= MmHGNu69VQ>? MV20PIg> M{C5cJNpcW[2IHnuJGczKHCqYYPl NFjmT|MzOjV2M{i1Oy=>
HT-29 and HCT-116 NYOzdFE3S2G|cHHz[UBie3OjeR?= M{TwdlXPxE1? M1nz[FI1cA>? MoXhbY5lfWOnczDjZZNx[XOnIHHjeIl3cXS7 M4fhZ|IzPTR|OEW3
MM cell lines Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNO69VQ>? NYf2Xnp2OjSq NUHaelh2TE2VTx?= NFe1OWZKSzVyII\hdolmeyCjbX;u[{BlcW[oZYLlcpQh[2WubDDsbY5meyCrbjD0bY1mKGGwZDDkc5NmKGSncHXu[IVv[2V? MXmyNlIxPzR6NR?=
ARP-1 MnPORZBweHSxc3nzJGF{e2G7 NXPoPJpHOTEQvF2= MkjBNlRp NHjxXZZFVVOR MWTpcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w MUmyNlIxPzR6NR?=
SNU-601 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzmR4hEPzKq NVvSdJlCTE2VTx?= M1jPemlEPTB;MD64NVbDuTBwME[z{txO NEH0c|QzOjF3OUixOC=>
SNU-1 NYO4N5Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rPWVczcA>? NVmwfGxGTE2VTx?= MoroTWM2OD1zLkC4NuKyOC5yMklOwG0> MlPRNlIyPTl6MUS=
SNU-668 NXi1SoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS3Nog> M4jMSWROW09? MW\JR|UxRTFwNUe5xtExNjB5NN88US=> M13nWVIzOTV7OEG0
AGS M2DoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOxO|Jp MojpSG1UVw>? MWTJR|UxRTFwN{G0xtExNjFzN988US=> MX6yNlE2QThzNB?=
SNU-216 MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Wy[VczcA>? M362VmROW09? MmTaTWM2OD1{Lk[5NuKyOC5yOENOwG0> Mnv3NlIyPTl6MUS=
SNU-5 M1mzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm2OIM4Omh? MmTESG1UVw>? NGfZbXdKSzVyPUGuN|UyyrFyLkC5Ne69VQ>? NEnocFUzOjF3OUixOC=>
SNU-638 NYThRVlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfZeZM4Omh? NGjaVmRFVVOR M3Lxd2lEPTB;Mj6yPFLDuTBwMEWz{txO MoTPNlIyPTl6MUS=
SNU-16 NX7xb|RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDtdY04Omh? MkXMSG1UVw>? MXXJR|UxRTFwNUezxtExNjByMd88US=> M{PQdFIzOTV7OEG0
SNU-484 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\ETo44Omh? MlvsSG1UVw>? M{XsU2lEPTB;MT63NljDuTBwMES1{txO M{nUPVIzOTV7OEG0
SNU-620 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HmfVczcA>? MkLjSG1UVw>? MUHJR|UxRTJwOUO5xtExNjByMd88US=> MY[yNlE2QThzNB?=
SNU-719 NUXsUYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUW3Nog> NXvZZXNjTE2VTx?= MUTJR|UxRTNwMEO3xtExNjB|Mt88US=> M3uxZ|IzOTV7OEG0
glioma cell lines MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LDO|czcA>? MWPJR|UxRTFvMt88US=> MnK5NlIxPjVyOEC=
U87 M1\n[mFxd3C2b4Ppd{BCe3OjeR?= M3nXd|LPxE1? Mm\4O|Jp NGXLNo5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHHu[EBkdGWjdnXkJHBCWlBiYX7kJINie3Cjc3WtNy=> MoHYNlIxPjVyOEC=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
- Collapse

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
- Collapse
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Drug: BKM120 Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01953445 Withdrawn Drug: paclitaxel|Drug: BKM120 Breast Neoplasms Washington University School of Medicine August 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID